3E Acquires Workplace Safety Provider, Quick-FDS
3.4.2024 10:00:00 EEST | Business Wire | Press release
3E, the leading global provider of intelligent compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, has completed its previously announced acquisition of Quick-FDS, the leading provider of workplace safety solutions in France. The acquisition of Quick-FDS from WEKA Group further expands 3E’s presence in Europe and establishes a leading position in the French market in particular.
Quick-FDS partners with both global manufacturers and downstream users of chemical products, providing mission-critical solutions that enable improved regulatory compliance and workplace safety. The Company has developed a highly specialized knowledge base and resource library of Safety Data Sheets (“SDS”), allowing many of the world’s largest companies to comply with both local and global regulatory pressures.
“We are thrilled to welcome Quick-FDS’ team, clients and partners into the broader 3E organization. Expanding in the French market has been a high priority for 3E and we are excited to accelerate our growth in the country through the combination of two industry-leading businesses,” said Greg Gartland, Chief Executive Officer of 3E. “This combination further solidifies 3E as the global leader in SDS management, empowering clients to improve chemical and workplace safety in a world with increasingly complex regulations.”
Deep knowledge and understanding of continuously evolving regulations have become critical for companies in and adjacent to the chemical industry. REACH regulations in the EU require all suppliers of chemicals to provide a unique Safety Data Sheet for each chemical substance to their customers. Quick-FDS’ market-leading solution enables compliance with REACH and a variety of other EU regulations, allowing customers to execute on their strategic goals while adhering to increasingly stringent requirements.
Robin Dualé, Managing Director of WEKA Group in France, said “This combination represents a significant milestone in the EHS&S industry, bringing together two of the most sophisticated providers of SDS management, workplace safety, and product stewardship solutions in Europe. The breadth of solutions that the combined company will be able to provide to clients is unparalleled, allowing for more informed decisions while reducing regulatory risks consistently, efficiently, and confidently.”
“This combination is highly strategic as 3E continues to expand its presence in Europe and across the globe,” added JP O'Sullivan, Chief Operating Officer at 3E. "With the combined strengths and capabilities of both 3E and Quick-FDS, we remain deeply committed to offering safety and compliance solutions to our clients and will be able to provide greater value and expertise as we serve an expanding global customer base."
3E has been active in strategic acquisition efforts since its separation from Verisk, having acquired Toxnot, Chemycal, ChemChain, and now Quick-FDS since March of 2022.
Shearman & Sterling LLP and Proskauer Rose LLP serve as the legal advisors to 3E. WEKA Group and Quick-FDS are advised by Carlsquare (M&A) and Astura (Legal).
About Quick-FDS
Quick-FDS provides digital workflow solutions related to Safety Data Sheet management to help manufacturers and end-users along the full supply chain for chemical products comply with global regulations, including European REACH. Quick-FDS’ historical success is driven by tight integration with compliance-related workflows throughout the chemical and specialty materials sector. Global chemical manufacturers, distributors, and wholesalers strongly endorse Quick-FDS as a true partner within their broader regulatory strategy.
About 3E
For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3Eco.com
About WEKA Group
WEKA Group is a diversified group of media companies and a leading provider of specialist information and advanced education with 15 operational companies in Germany, Austria, and France. WEKA Group’s media-neutral content is offered in all common formats and reaches highly diversified niche markets across all industries. WEKA Group is headquartered in Kissing, Germany, and employs approximately 1,000 employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328295790/en/
Contact information
Media:
Maria Rutland
3E
maria.rutland@3eco.com
+1.760.987.5152
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom